NEOG
NEOGEN CORP
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$11.63
−1.52%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 884.0M | 870.4M | 894.7M | 924.2M | 822.4M |
| Cost of Revenue | 465.0M | 461.9M | 473.3M | 461.6M | 416.5M |
| Gross Profit | 419.0M | 408.5M | 421.4M | 462.6M | 406.0M |
| Operating Expenses | |||||
| R&D Expense | 19.8M | 18.4M | 21.1M | 22.5M | 26.0M |
| SG&A Expense | 406.6M | 411.7M | 402.0M | 382.8M | 342.4M |
| General & Admin Expense | 243.5M | 245.1M | 218.2M | 199.9M | 201.2M |
| Selling & Marketing Expense | 163.1M | 166.6M | 183.8M | 182.9M | 141.2M |
| Other Expenses | — | — | (9.0M) | (20.0M) | — |
| Total Operating Expenses | 426.4M | 430.1M | 412.0M | 385.2M | 368.4M |
| Cost and Expenses | 891.4M | 892.0M | 885.2M | 846.8M | 784.9M |
| Operating Income (EBIT) | (7.4M) | (21.6M) | 9.4M | 77.4M | 37.5M |
| Non-Operating | |||||
| Interest Income | 592.0K | — | 3.1M | 6.4M | 3.2M |
| Interest Expense | 56.4M | 57.6M | 71.6M | 73.4M | 56.0M |
| Net Interest Income | (55.9M) | (57.6M) | (68.5M) | (67.0M) | (52.8M) |
| Other Non-Op Income/Expense | (60.3M) | 12.6M | (1.1B) | (91.7M) | (59.6M) |
| Non-Operating Income (excl Interest) | 3.8M | (70.2M) | 1.1B | 16.1M | 3.6M |
| EBT (Pre-Tax Income) | (67.7M) | (9.0M) | (1.1B) | (14.3M) | (22.0M) |
| Income Tax Expense | (11.5M) | (1.1M) | (41.1M) | (4.9M) | 828.0K |
| Bottom Line | |||||
| Net Income | (56.1M) | (7.9M) | (1.1B) | (9.4M) | (22.9M) |
| Earnings from Cont. Ops | (56.1M) | (7.9M) | (1.1B) | (9.4M) | (22.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (56.1M) | (7.9M) | (1.1B) | (9.4M) | (22.9M) |
| Per Share | |||||
| Basic EPS | ($0.25) | ($0.04) | ($5.03) | ($0.04) | ($0.12) |
| Diluted EPS | ($0.25) | ($0.04) | ($5.03) | ($0.04) | ($0.12) |
| Revenue Per Share | $4.05 | $4.00 | $4.12 | $4.27 | $4.35 |
| Shares | |||||
| Basic Shares Outstanding | 218.1M | 217.5M | 216.9M | 216.5M | 188.9M |
| Diluted Shares Outstanding | 218.1M | 217.5M | 216.9M | 216.5M | 188.9M |
| Profitability Metrics | |||||
| EBITDA | 105.1M | 164.9M | (937.8M) | 182.6M | 124.4M |
| D&A | 116.3M | 116.3M | 125.7M | 121.2M | 90.5M |
| EBIT | (11.2M) | 48.6M | (1.1B) | 61.4M | 33.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026